Literature DB >> 26467676

Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis.

Margherita Fabbri, Giorgio Leodori, Ricardo M Fernandes, Roongroj Bhidayasiri, Maria Jose Marti, Carlo Colosimo, Joaquim J Ferreira.   

Abstract

The formation of neutralizing antibodies (NAbs) directed specifically against the active neurotoxin part of the botulinum neurotoxin (BoNT) complex is often cited as a major cause of secondary non-responsiveness (SnR) to treatment. This systematic and meta-analytic review evaluates the frequency of NAbs among patients treated with BoNT therapy for any clinical indication. A comprehensive database search strategy was designed to retrieve relevant clinical data from the published literature up to April 2013. All English-language publications that analyzed NAbs prevalence in more than ten patients were included, regardless of BoNT formulation, assay method, and study design. For the meta-analysis, patients were divided into three categories: secondary nonresponse (SnR) patients, clinically responding patients and all patients, independently of BoNT responsiveness. The meta-analysis included 61 studies reporting data for 8525 patients; 4972 dystonic patients, 1170 patients with spasticity, 294 patients with urologic indications, 396 patient with hyperhidrosis, 1659 patients with glabellar line, and 34 patients with hypersalivation. Among the ‘‘all patients’’ group NAbs frequency was 20%for dystonia, 5.9%for spasticity, and 2.7% for urologic patients and 1.1% for other conditions. The prevalence of NAbs was lower (3.5%) among clinically responding patients and higher in 53.5%SnR patients. About a half of patients with SnR do not have NAbs. NAbs was high among patients treated with RIMA but it was not associated with clinical non-responsiveness. Meta-analysis of the frequency of NAbs and SnR are limited by the heterogeneity of study design and reported outcomes. Indeed the analysis of several factors that can influence the development of NAbs, i.e.,MHCof patients, frequency and site of injection, injection technique, cumulative dose, and toxin denaturation, was not specifically evaluated due to the paucity and heterogeneity of data. The identification of all these missing data should be taken into account in order to improve the methodology of future studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26467676     DOI: 10.1007/s12640-015-9565-5

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  31 in total

Review 1.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

2.  Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.

Authors:  J Jankovic; C Hunter; B Z Dolimbek; G S Dolimbek; C H Adler; A Brashear; C L Comella; M Gordon; D E Riley; K Sethi; C Singer; M Stacy; D Tarsy; M Z Atassi
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 3.  Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.

Authors:  D Dressler; M Hallett
Journal:  Eur J Neurol       Date:  2006-02       Impact factor: 6.089

4.  Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test.

Authors:  Carla Cordivari; Vijay Peter Misra; Angela Vincent; Santiago Catania; Kailash P Bhatia; Andrew John Lees
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

5.  Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.

Authors:  Robert B Chinnapongse; Mark F Lew; Joaquim J Ferreira; Kristen L Gullo; Paul R Nemeth; Yuxin Zhang
Journal:  Clin Neuropharmacol       Date:  2012 Sep-Oct       Impact factor: 1.592

6.  Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.

Authors:  Behzod Z Dolimbek; K Roger Aoki; Lance E Steward; Joseph Jankovic; M Zouhair Atassi
Journal:  Mol Immunol       Date:  2006-05-02       Impact factor: 4.407

7.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

8.  Development of resistance to botulinum toxin type A in patients with torticollis.

Authors:  P Greene; S Fahn; B Diamond
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

9.  Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.

Authors:  P A Hanna; J Jankovic
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 10.  Clinical relevance of botulinum toxin immunogenicity.

Authors:  Reiner Benecke
Journal:  BioDrugs       Date:  2012-04-01       Impact factor: 5.807

View more
  25 in total

1.  Botulinum Toxin Use in Neurourology.

Authors:  Benoit Peyronnet; Xavier Gamé; Gregory Vurture; Victor W Nitti; Benjamin M Brucker
Journal:  Rev Urol       Date:  2018

Review 2.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

Review 3.  Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.

Authors:  Gonçalo S Duarte; Mafalda Castelão; Filipe B Rodrigues; Raquel E Marques; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2016-10-26

4.  Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus.

Authors:  Wilson W S Ho; Philipp Albrecht; Pacifico E Calderon; Niamh Corduff; David Loh; Michael U Martin; Je-Young Park; Lis S Suseno; Fang-Wen Tseng; Vasanop Vachiramon; Rungsima Wanitphakdeedecha; Chong-Hyun Won; Jonathan N T Yu; Mary Dingley
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-06-20

Review 5.  Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.

Authors:  Andrea Santamato; Francesco Panza
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 6.  Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Authors:  H A Jinnah; Cynthia L Comella; Joel Perlmutter; Codrin Lungu; Mark Hallett
Journal:  Toxicon       Date:  2017-09-06       Impact factor: 3.033

7.  Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.

Authors:  H A Jinnah; Emily Goodmann; Ami R Rosen; Marian Evatt; Alan Freeman; Stewart Factor
Journal:  J Neurol       Date:  2016-04-25       Impact factor: 4.849

8.  Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Authors:  Pamela Latino; Letizia Castelli; Luca Prosperini; Maria Rita Marchetti; Carlo Pozzilli; Morena Giovannelli
Journal:  Neurol Sci       Date:  2017-08-01       Impact factor: 3.307

9.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

10.  Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

Authors:  Jörg Wissel; Djamel Bensmail; Joaquim J Ferreira; Franco Molteni; Lalith Satkunam; Susana Moraleda; Tiina Rekand; John McGuire; Astrid Scheschonka; Birgit Flatau-Baqué; Olivier Simon; Edward T J Rochford; Dirk Dressler; David M Simpson
Journal:  Neurology       Date:  2017-03-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.